

MONOCLONAL ANTIBODIES: A PROMISING WEAPON AGAINST THE SILENT PAN-DEMIC OF MULTIDRUG-RESISTANT BACTERIA

Authors

Manoj Kumar Jana

Department of Biotechnology
Kiit University
Odisha, India.

Ming-Hsien Chiang

Fu Jen Catholic University
No.510, Zhongzheng Rd.
Xinzhuan, New Taipei City 242062
Taiwan (R.O.C.)
vincent4811@gmail.com
8860986027808

The global threat of antimicrobial resistance (AMR) has reached critical levels, presenting an unprecedented challenge to public health and economic stability worldwide. (Cassini et al., 2019; CDC, 2019). Recent data paint a stark picture: annually, AMR is responsible for an estimated 1.27 million deaths globally, with projections suggesting this could rise to 10 million by 2050 if current trends persist (O'Neill, 2014). In the United States alone, more than 2.8 million antibiotic-resistant infections occur each year, resulting in over 35,000 deaths (CDC, 2022). The COVID-19 pandemic has further exacerbated this crisis. Despite guidelines recommending against routine antibiotic use for SARS-CoV-2 infections, a comprehensive study revealed that nearly 75% of COVID-19 patients received prophylactic antibiotics, even though only 8.6% had confirmed bacterial co-infections (Langford et al., 2021). This widespread misuse of antibiotics has accelerated the development of resistance. Following the peak of the pandemic, the U.S. Centers for Disease Control and Prevention reported a alarming 15% increase in hospital-acquired antimicrobial-resistant infections (Antimicrobial Resistance, 2022). Particularly concerning is the rise in resistant strains of common pathogens, including MRSA, VRE, MDR *Pseudomonas aeruginosa*, and carbapenem-resistant *Acinetobacter*, which collectively account for a significant proportion of AMR-related deaths.

The urgency for effective infection control against antibiotic-resistant bacteria in the current era is a critical concern. As bacterial resistance becomes more prevalent and complex, global awareness of essential infection control measures is expanding, particularly within healthcare settings (Ghoneim et al., 2013). These measures encompass rigorous environmental cleaning, advanced disinfection technologies, stringent hand hygiene practices, and the prudent use of antibiotics to curb further resistance. Additionally, there is a growing emphasis on antimicrobial stewardship programs and the adoption of rapid diagnostic technologies to guide appropriate antibiotic utilization (Frost et al., 2023). Despite concerted efforts, the period from 2020 to 2023 witnessed a disappointingly low number of new antibiotic approvals, with only a few novel compounds entering the market (Butler et al., 2023). Alarming, the pace of drug resistance development continues to outstrip that of new drug discoveries significantly, leading to a widening gap in our antimicrobial arsenal (Batchelder et al., 2023). This trend is particularly worrisome with the emergence of pan-resistant bacterial strains that are impervious to all existing antibiotics (Kim et al., 2023a). The challenge is

further exacerbated by the economic realities of antibiotic development, with many pharmaceutical companies scaling back or discontinuing their antibiotic research programs due to low returns on investment, resulting in an innovation gap in this crucial area (Kim, et al., 2023a). Given this challenging scenario, it is imperative to explore innovative approaches beyond traditional antibiotics to combat bacterial infections. Promising alternative strategies include the development of immunotherapies like vaccines and monoclonal antibodies (mAbs) targeted at combating multidrug-resistant (MDR) bacteria (McCulloch et al., 2022; Seixas et al., 2022). These approaches offer several advantages over traditional antibiotics, including high specificity, potentially lower risk of resistance development, and the ability to leverage the host immune system's power (Elemam et al., 2021). Furthermore, recent advancements in biotechnology, such as artificial intelligence (AI)-driven antibody design and novel antibody engineering techniques, have unlocked new possibilities in this domain. By leveraging AI technologies, researchers have been able to accelerate the discovery of antibodies through the design of targeted libraries enriched for specific binding properties, thereby reducing the need for extensive experimental screening (Chungyoun and Gray, 2023).

I. CHALLENGES IN DEVELOPING VACCINES FOR BACTERIAL INFECTIONS

From the development of human medicines to the recent battles with COVID-19, vaccines have consistently proven to be among the most cost-effective methods for preventing infectious diseases, even in immunocompromised groups (**Antinori and Bausch-Jurken, 2023**). Research has particularly highlighted the cost-effectiveness of vaccinating against MDR bacteria, especially in children under five and in lower-middle-income to low-income countries where the disease burden is notably high (Anderson et al., 2023; Lee et al., 2023). For instance, a study in the US found that the pneumococcal conjugate vaccine (PCV13) halved the rates of antibiotic-resistant invasive pneumococcal diseases across all age groups, from 61% to 27% (**Bajema et al., 2022**). Additionally, typhoid conjugate vaccines (TCV) have shown substantial efficacy in curbing the spread of *Salmonella typhi* in impoverished regions. The WHO has systematically validated the effectiveness of TCV in controlling typhoid fever in endemic areas and supports its integration into routine vaccination programs in high-risk countries (Saha et al., 2021). As antibiotics continue to lose their effectiveness, the urgency to develop new therapeutic strategies to tackle evolving MDR bacterial strains is more pressing than ever (Stokes et al., 2019). The focus on vaccines has shifted from theoretical discussions to active investigations of their practicality in clinical settings (Jansen et al., 2018; Buchy et al., 2020). Vaccination could be a strategic response to antibiotic resistance, particularly if it significantly reduces antibiotic use in high-consumption subpopulations (Davies et al., 2021). Nevertheless, the development of vaccines for MDR bacteria faces three significant challenges: technical complexities, identification of target groups, and economic feasibility (López-Siles et al., 2020).

Initially, the technical challenge involves identifying an appropriate vaccine candidate by leveraging previous methodologies that use virulence factors, surface sugar molecules, capsules, or outer membrane proteins as antigens. This is followed by the utilization of bioinformatics to screen for proteins that exhibit potential as epitopes, focusing particularly on those that are surface-exposed and highly conserved. Moreover, translating results from animal models to human clinical trials presents significant hurdles due to variations in cytokine expression levels and differences in immunological responses between humans and

rodents (Mak et al., 2014). After these extensive and resource-intensive verification steps, only a handful of candidates emerge as successful (Chiang et al., 2015; Michalik et al., 2016).

Identifying the primary target groups for vaccination is crucial. Currently, vaccinations are primarily directed towards high-risk individuals, including patients in intensive care units, those with chronic conditions, ventilator users, cancer patients, and those undergoing surgery. However, the effectiveness of preoperative vaccinations or those administered at the onset of disease is limited. Defining high-risk groups in practical terms remains a challenge, which may hinder broader vaccine promotion and utilization.

The market for vaccines against MDR bacteria is relatively small. According to the U.S. Centers for Disease Control and Prevention, around 2.8 million patients contract MDR bacterial infections annually (CDC, 2019). Although this figure is substantial, the incidence rate of these infections is lower compared to other diseases, yet they present higher mortality rates. Furthermore, MDR bacterial infections associated with healthcare settings significantly increase costs due to extended stays in intensive care units and prolonged hospital admissions (Pasero et al., 2021). Despite the potential impact, the economic incentives for biopharmaceutical companies are limited. The substantial investment required for research and development, coupled with short profit margins and product lifespans, renders this sector less appealing compared to more lucrative areas such as cancer treatment.

In light of the ongoing challenge posed by MDR bacterial infections and the relentless development of new antibiotics struggling to keep pace with drug resistance, exploring alternative treatment approaches becomes crucial. One such promising method is the development of therapeutic mAbs, which may offer a more viable strategy (McConnell, 2019; López-Siles, et al., 2020). Unlike vaccines, which typically require several weeks to elicit protective immunity?

mAbs can provide immediate protection upon administration. This review aims to deliver a comprehensive examination of the role of mAbs in combating MDR bacterial infections. It will cover the mechanisms through which mAbs function, delve into ongoing research and clinical trials, and discuss the challenges and limitations that accompany mAb treatments. Additionally, this review will provide a comparative analysis of mAbs against other treatments for MDR infections, addressing the regulatory and ethical considerations involved in their use. Ultimately, the goal is to furnish insights into the future possibilities of mAb therapies in the realm of MDR bacterial infections, thereby informing and guiding further research and development efforts in this pivotal area.

II. ADVANCEMENTS IN THE DEVELOPMENT OF ANTIBACTERIAL MONOCLONAL ANTIBODIES

MAbs are homogeneous antibodies produced from a single B-cell clone, each capable of targeting a specific epitope on an antigen. Historically, despite the availability of numerous antibiotics, the cost of utilizing mAbs as a treatment option was prohibitively high, leading to slower development in this field compared to cancer and autoimmune diseases (Monserrat-Martinez et al., 2019; Lu et al., 2020). Today, propelled by advancements in precision medicine and biotechnology, the demand for mAbs in anti-infective clinical applications is increasing. To appreciate the potential of mAbs, it's important to understand the diverse roles

of immunoglobulin isotypes in the immune response. Immunoglobulins, also known as antibodies, are proteins produced by B cells that play a crucial role in defending the body against pathogens. There are five major isotypes of immunoglobulins (IgD, IgE, IgM, IgA, IgG), each with distinct functions and distributions within the body (Fig. 1).




Figure 1: Functional activities of different immunoglobulin isotypes.

The table summarizes the key functions of the five major antibody isotypes (IgD, IgE, IgM, IgA, IgG) and the four subclasses of IgG (IgG1, IgG2, IgG3, IgG4) in the immune response. These functions include neutralization of pathogens, opsonization (facilitating phagocytosis), activation of natural killer (NK) cells, sensitization of mast cells (leading to degranulation and release of inflammatory mediators), and activation of the complement system (a cascade of proteins that help clear pathogens). The number of "+" symbols indicates the relative strength of each isotype's activity in a particular function, with "+++" being the highest. The "-" symbol indicates that the isotype does not perform that function.

MAbs are primarily categorized into four types based on their origin: mouse-derived, human-mouse chimeric, humanized, and fully human mAbs (Maynard, 2021) (Fig. 2). Mouse derived mAbs, the first generation of mAb technology, are hybridomas created by fusing B lymphocytes from immunized mice with mouse myeloma cells, widely used in foundational antibody research. Human-mouse chimeric mAbs result from the genetic recombination of the mouse antibody's variable region (Fv) gene with the constant region (Fc) of the human antibody, retaining about 30% of murine antibody characteristics (Hwang and Foote, 2005). Humanized mAbs are crafted by replacing murine mAb complementarity-determining regions (CDRs) with those in human antibodies, achieving approximately 90% humanization (Harding et al., 2010), thus maintaining the specificity of murine mAbs while being more compatible with human systems. Fully human mAbs, considered the optimal choice for therapy, are produced using techniques such as phage antibody library expression, ribosome display, and transgenic mouse technology (Klemm et al., 2021). These mAbs completely eliminate interspecies heterogeneity, reducing the risk of human anti-chimeric antibody (HACA) reactions (Hwang and Foote, 2005; Kang and Seong, 2020).




Figure 2: Progression of monoclonal antibody development

This figure illustrates the progression of mAb technology over time, focusing on the reduction of immunogenicity. (A) Bar graph showing the relative immunogenicity of four mAb generations: murine, chimeric, humanized, and fully human. The decreasing height of bars represents reduced immune system reactivity. (B) Timeline of mAb development, displaying three key attributes for each generation: (i) generic nomenclature, (ii) percentage of murine components, and (iii) year of first identification. The gradual decrease in murine content correlates with improved clinical applicability. CDRs: complementarity-determining regions. This figure demonstrates how antibody engineering has advanced to produce mAbs with enhanced therapeutic potential and reduced risk of adverse immune responses.

Compared to traditional antibiotics, mAbs offer several distinct advantages for treating bacterial infections: (1) High specificity, effectively targeting MDR bacteria without affecting normal intestinal flora (Wang-Lin and Balthasar, 2018); (2) A strong safety profile; (3) The potential to be used in conjunction with standard antibiotics as antibody-drug conjugates, which can reduce dosage requirements and minimize selective pressure (Mariathan and Tan, 2017); (4) Enhanced affinity and safety through genetic modifications, such as the development of single-chain fragment variable (scFv) antibodies and fully human antibodies (Hwang and Foote, 2005; Kang and Seong, 2020); (5) Extended half-life, ensuring sustained bioavailability and offering benefits in dosing compliance and adherence (Wang-Lin and Balthasar, 2018); (6) Vital therapeutic benefits for immunocompromised patients or those unsuitable for vaccination (Motley et al., 2019); (7) Environmentally friendly production processes that use minimal chemical agents (Pietrzykowski et al., 2013); (8) Absence of environmental accumulation, unlike antibiotics; (9) Lower likelihood of developing drug resistance, due to targeting specific virulence factors rather than essential survival proteins (Sziórtó et al., 2018). In addition, mAbs are currently being explored in several clinical trials as potential adjuncts to antibiotic therapy, showing promise in enhancing treatment outcomes while aiming to reduce or replace the use of antibiotics (Zhou et al., 2016; Mariathan and Tan, 2017; Cavaco et al., 2022).

Despite their advantages, all mAbs are recognized as foreign by the recipient's immune system, which can lead to the production of neutralizing antibodies or pathological immune responses. Chimeric mAbs inherently contain murine elements that may induce HACA responses. Similarly, humanized and fully human mAbs might trigger anti-drug antibody reactions, potentially impacting their pharmacokinetics (PK) and therapeutic efficacy (Wang-Lin and Balthasar, 2018).

III. ONGOING RESEARCH AND CLINICAL INVESTIGATIONS

The landscape of antibacterial mAb development is rapidly evolving, with numerous clinical trials underway (Medicine, 2023). A comprehensive analysis of data from ClinicalTrials.gov reveals a diverse array of targets and approaches for these novel therapeutics (Table 1). The ongoing clinical trials can be categorized based on target pathogens and mechanisms of action:

***Staphylococcus Aureus*-Targeted mAbs:** Several mAbs are in development against *S. aureus*, targeting various virulence factors. Tefibazumab, a humanized mAb, targets clumping factor A, while 514G3 targets the cell wall moiety Protein A. MEDI4893 (suvratoxumab) and AR-301 (tosatoxumab) both target alpha-hemolysin, a key virulence factor. ASN-100, a combination of two human mAbs, targets multiple toxins including alpha-hemolysin and leucocidins (Yang et al., 2016). The multifaceted strategies involving different mAbs targeting various toxins and proteins of *S. aureus* underscore the complexity of *S. aureus* pathogenicity and the necessity for diverse therapeutic interventions (Raafat et al., 2019).

***Pseudomonas Aeruginosa*-Targeted mAbs:** *P. aeruginosa*, a significant cause of hospital-acquired infections, is the target of several mAbs in development. KB001 and MEDI3902 target the type III secretion system protein PcrV (Warrener et al., 2014), has shown promise in preclinical studies, with some antibodies proving to be safe and well-tolerated. AR-105 (Aerucin) targets alginate, while KBPA-101 (Aermab) targets the O-antigen of lipopolysaccharide. Interestingly, PsAer-IgY, derived from chicken egg yolk, targets flagellin, showcasing the diversity of antibody sources being explored (Frank et al., 2002).

***Clostridium Difficile*-Targeted mAbs:** Building on the success of bezlotoxumab, other mAbs targeting *C. difficile* toxins are in development. MK-3415A combines antibodies against both toxin A and B, while GS-CDA1/MDX-1388 targets toxin A and a fragment of toxin B (Wilcox et al., 2017). Furthermore, the mechanism of action and epitopes of bezlotoxumab, a neutralizing antibody targeting *C. difficile* toxin B, have been elucidated through X-ray crystallography, providing insights into how this antibody neutralizes the toxin (Orth et al., 2014). These antibodies offer targeted strategies to neutralize the virulence factors produced by *C. difficile*, potentially reducing the recurrence and severity of CDI.

Bioterrorism Defense: *Bacillus anthracis* toxins consist of three proteins: protective antigen (PA), lethal factor (LF), and edema factor (EF), which interact in a binary fashion to produce edema toxin (PA plus EF) and lethal toxin (PA plus LF; LeTx). Raxibacumab, obiltoximab, and other mAbs targeting the PA component of *Bacillus anthracis* toxin represent critical advancements in biodefense (Little et al., 2011). These mAbs are approved

to treat inhalation anthrax and have received significant attention due to their potential role in counter-bioterrorism measures.

Broad-Spectrum Approaches: Some mAbs in development aim for broader applicability. F598, for instance, targets poly-N-acetylglucosamine (PNAG), a surface polysaccharide found in multiple bacterial species (Soliman et al., 2020). This approach could potentially lead to therapies effective against a wide range of pathogens.

Novel Targets and Approaches: The clinical trials also reveal exploration of novel targets. For example, TRL1068 and CMTX-101 target biofilm scaffolding proteins, addressing the challenging issue of bio-film-associated infections (Ryser et al., 2019). XJ103, targeting α -isopropylmalate dehydrogenase in *Streptococcus pneumoniae*, represents an innovative approach to pneumococcal infections.

These diverse approaches in mAb development reflect the complexity of bacterial pathogenesis and the need for multi-faceted strategies to combat antibiotic resistance. By targeting specific virulence factors, toxins, and conserved surface structures, these mAbs aim to neutralize bacterial pathogenicity without directly killing the bacteria, potentially reducing the selective pressure that leads to antibiotic resistance. The success of bezlo-toxumab (Zinplava) against *C. difficile* infections serves as a proof of concept, demonstrating the clinical viability of mAb-based therapies for bacterial infections. Approved by the FDA in 2016, this human IgG1 antibody effectively reduces recurrent infections in high-risk patients, particularly those on antibiotic regimens or with compromised gastrointestinal health (Wilcox, et al., 2017).

Moreover, some mAbs show promise in addressing antibiotic resistance through novel mechanisms. For instance, antibodies targeting the type 3 secretion system in *P. aeruginosa* or outer membrane proteins in *Acinetobacter baumannii* and *Salmonella* species may help restore antibiotic sensitivity. A groundbreaking study by Huang et al. (2019) demonstrated that antibodies against *A. baumannii* outer membrane vesicles could significantly enhance the efficacy of levofloxacin and ciprofloxacin against multidrug-resistant strains, both in vitro and in vivo (Huang et al., 2019). As research progresses, the potential applications of mAbs in infectious disease management continue to expand. The diversity of targets and mechanisms represented in ongoing clinical trials highlights the versatility of this therapeutic approach. From species-specific interventions to broad-spectrum strategies, and from toxin neutralization to biofilm disruption, mAbs offer a promising arsenal in the fight against antibiotic-resistant infections.

Table 1: The Ongoing Clinical Trials for Anti-Bacterial mAbs are Accessible on ClinicalTrials.gov (accessed on 1 June 2024).

Agents	Bacterial Species	Target	Sponsor	Phase	NCT no.	Immunogenicity
Tefibazumab	<i>Staphylococcus aureus</i>	clumping factor A	Bristol-Myers Squibb	II	NCT00198289	Humanized
514G3		cell wall moiety Protein A (SpA)	XBiotech	II	NCT02357966	Human (isolated and cloned from a healthy human donor)
MEDI4893 (Suvratoxumab)		alpha-hemolysin	Medimmune	II	NCT02296320	Human (VelocImmune mice)
ASN-100 (ASN- 1 and ASN-2)		alpha-hemolysin, gamma-hemolysin, bicomponent leucocidin (HlgAB, HlgCB, LukED, LukSF, and LukGH)	Arsansis	II	NCT02940626	Human
AR-301 (Tosatoxumab)		alpha toxin	Aridis Pharmaceuticals	II	NCT03816956	Human (convalescent patient B-cell)
DSTA-4637S		Teichoic Acid (Antibody-Antibiotic Conjugate)	Genentech and Roche	I	NCT03162250	Human
Aurograb®		ABC transporter GrfA	NeuTec Pharma / Novartis	II	NCT00217841	scFv
KB001	<i>Pseudomonas aeruginosa</i>	type III secretion system, PcrV	KaloBios	II	NCT00638365	humanized PEGylated Fab
PsAer-IgY		surface protein (Flagellin)	Mukoviszidose Institut gGmbH	II	NCT01455675	Chicken egg yolk
AR-105 (Aerucin)		alginate	Aridis Pharmaceuticals	II	NCT03027609	Human
KBPA-101 (Aermab)		LPS O-antigen (serotype O11)	Aridis (Kenta Biotech)	II	NCT00851435	Human
MEDI3902		type III secretion system, PcrV, exopolysaccharide, Psl	Medimmune	II	NCT02696902	Human (bispecific phage display and VelocImmune mouse)
MK-3415A (actoxumab-bezlotoxumab)			toxin A/B	Merck Sharp & Dohme	II	NCT01513239

**MONOCLONAL ANTIBODIES: A PROMISING WEAPON AGAINST
THE SILENT PAN-DEMIC OF MULTIDRUG-RESISTANT BACTERIA**

Bezlotoxumab (Zinplava®)	<i>Clostridium difficile</i>	toxin B	Merck Sharp & Dohme	IV	NCT03880539	Human
GS-CDA1/MDX- 1388		toxin A/ C-terminal toxin B fragment	MassBiologics/ Merck	II	NCT00350298	human
Raxibacumab (ABthrax®/Anth rin®)	<i>Bacillus anthracis</i>	protective antigen (PA) component of anthrax toxin	Human Genome Sciences	IV	NCT02177721	Human (phage display)
Obiltoximab (Anthim®, ETI- 204)		PA component of anthrax toxin	Elusys Therapeutics	IV	NCT03088111	Human-mouse (hybridoma)
MDX-1303 (Valortim®)		Uncleaved and cleaved PA	PharmAthene	I	NCT00964561	Human
AVP-21D9 (Thraxixa™)		PA component of anthrax toxin	Emergent BioSolutions	I	NCT01202695	Human
NTM-1632/3		<i>Clostridium botulinum</i>	botulinum neurotoxin type B	NIAID	I	NCT02779140
XOMA 3ab		botulinum neurotoxin type B	XOMA/NIAID	I	NCT01357213	Humanized
A82 / B86	<i>Clostridium Tetanus</i>	anti-tetanus toxin	Changchun BCHT Biotechnology Co.	I	NCT06360250	Human
TRL1068	<i>Biofilm— multiple species</i>	biofilm scaffolding proteins DNABII	Trellis Bioscience	I	NCT04763759	Human
CMTX-101			Clarametyx Biosciences, Inc.	I	NCT05629741	Human
F598	<i>Multiple species</i>	Poly-N- acetylglucosamine (PNAG)	Alopexx Pharmaceuticals	II	NCT03222401	Human
Pagibaximab (BSYX-A110)	<i>Staphylococ cal Sepsis</i>	lipoteichoic acid	Biosynexus	II	NCT00646399	Humanized
XJ103	<i>Streptococ s pneumoniae</i>	α-isopropylmalate dehydrogenase	Starmab biologics Co.,Ltd	I	NCT06026748	humanized
caStx1/caStx2	Shiga Toxin- Producing <i>E.coli</i>	shiga toxins	Thallion Pharmaceuticals	II	NCT01252199	Humanized

IV. MECHANISMS OF ACTION: HOW MONOCLONAL ANTIBODIES COMBAT MDR BACTERIA

mAbs offer a multifaceted approach to combating MDR bacteria, targeting conserved surface antigens such as lipopolysaccharide (LPS), capsular polysaccharides, and outer membrane proteins. This specificity allows mAbs to recognize and attach to bacterial cells effectively, even in antibiotic-resistant strains (Seixas, et al., 2022). Figure 3 illustrates the diverse mechanisms by which mAbs combat MDR bacteria:

Neutralizing bacterial toxins and virulence factors (Fig. 3A): mAbs can bind to and neutralize toxins produced by bacteria, preventing them from damaging host cells. For instance, bezlotoxumab, an mAb developed to target *Clostridioides difficile* toxin B, has shown efficacy in reducing the recurrence of *C. difficile* infections (Zurawski and McLendon, 2020b). The figure shows mAbs neutralizing and inhibiting toxins before they can interact with the bacterial cell surface. **Blocking receptor binding (Fig. 3B):** mAbs can interfere with bacterial adhesion to host cells by binding to bacterial adhesins or host cell receptors. This mechanism prevents the initial attachment of bacteria to host tissues, a critical step in infection. **Antibody-Drug Conjugates (ADCs) (Fig. 3C):** This innovative approach combines the specificity of mAbs with the potency of antibiotics. ADCs allow for targeted delivery of antibiotics to bacterial cells, potentially increasing efficacy while reducing systemic exposure and side effects. **Inhibition/disruption of biofilm formation (Fig. 3D):** mAbs can target key bacterial surface structures involved in biofilm formation, a critical virulence factor for many MDR pathogens. For example, an mAb targeting the Psl exopolysaccharide of *Pseudomonas aeruginosa* has been shown to disrupt biofilm formation and restrict bacterial invasion in a mouse model of pneumonia (Zurawski and McLendon, 2020b). **NETosis and opsonophagocytosis (Fig. 3E):** By coating the bacterial surface, mAbs mark bacteria for phagocytosis (opsonization) and destruction by immune cells. This process enhances the host's natural immune response against the pathogen (Vacca et al., 2022). Additionally, mAbs can induce NETosis, where neutrophils release extracellular traps to capture and kill bacteria. **Complement-dependent cytotoxicity (Fig. 3F):** mAb binding can activate the complement system, leading to direct bacterial killing via membrane attack complexes (Zurawski and McLendon, 2020b). The figure illustrates how complement proteins (C1q) bind to antibodies on the bacterial surface, leading to phagocytosis and lysis. **Antibody-dependent cell-mediated cytotoxicity (ADCC) (Fig. 3G):** This mechanism involves the recruitment of immune effector cells, such as natural killer (NK) cells and cytotoxic T cells, to destroy antibody-coated bacteria. The figure shows how NK cells and CD8⁺ T cells interact with antibody-coated infected cells, releasing cytotoxic granules to kill the target.

The ability of mAbs to employ these diverse mechanisms makes them particularly effective against MDR strains, as the targeted antigens are often essential for bacterial virulence and survival (Vacca, et al., 2022). By disrupting multiple aspects of bacterial pathogenesis, from toxin neutralization to biofilm disruption and immune system activation, mAbs offer a comprehensive approach to combating antibiotic-resistant infections.




Figure 3: Mechanisms of mAb in combating bacterial infections.

This figure illustrates the intricate mechanisms through which mAbs combat bacterial infections. **A. Neutralization of Bacterial Virulence Factors:** mAbs neutralize or inhibit bacterial virulence factors, mitigating their pathogenic effects. **B. Blocking Bacterial Adhesion:** mAbs block receptor-mediated adhesion, preventing bacteria from attaching to host cells and hindering infection progression. **C. ADC Strategy:** mAbs conjugated with antibiotics enhance the precision and effectiveness of targeting and eliminating bacteria. **D. Disruption of Biofilm Formation:** mAbs inhibit or disrupt biofilm formation, a primary bacterial defense mechanism, thereby facilitating bacterial clearance. **E. mAb-Mediated NETosis/Opsonophagocytosis:** mAbs promote bacterial clearance by facilitating neutrophil extracellular traps (NETs) and enhancing phagocytosis. **F. Complement-Dependent Cytotoxicity:** mAbs activate complement-dependent cytotoxicity, leading to the lysis of bacterial cells. **G. Synergy Between Innate and Adaptive Immunity:** mAbs enhance the synergy between innate and adaptive immune responses in ADCC, promoting the clearance of bacterial infections (Lehar et al., 2015; Zurawski and McLendon, 2020a; Cavaco, et al., 2022; Wang et al., 2022).

Recent advancements in mAb development have ushered in a new era of multivalent and combinatorial strategies. This shift towards more complex antibody designs aims to neutralize antigens more extensively, closely mimicking the human natural immune system's polyclonal response (Gilchuk et al., 2020; Yadav et al., 2021). A groundbreaking study by

Buckley et al. (Buckley et al., 2023) exemplifies this approach, introducing an engineered multivalent protein biologic agent that targets five surface proteins and neutralizes five different *S. aureus* virulence factors simultaneously. This innovative construct is designed to resist proteolysis, avoid Fc binding to *S. aureus* IgG-binding proteins, and neutralize toxins. It features tandem centyrin moieties, small protein scaffolds derived from the fibronectin type III-binding domain, that bind to and neutralize two *S. aureus* leukocidins, thereby protecting phagocytes and enhancing their antimicrobial function. The development of multivalent mAbs has been further enhanced by collecting antibodies from multiple B-cell lineages, resulting in varying site affinities for the same pathogen. This diversity in binding profiles offers a broader range of neutralization options and significantly reduces the likelihood of pathogens developing escape mutations, thus inhibiting or slowing down the emergence of MDR bacteria (Kennedy and Read, 2017). The presence of multiple epitope binding sites in these advanced mAbs allows them to bind to numerous antigenic sites, potentially compensating for the gaps left by antibiotics and vaccines after treatment failure (Batchelder, et al., 2023). This approach is particularly promising for addressing chronic or recurrent infections that often result from incomplete clearance by standard therapies.

The integration of these multivalent mAb strategies with existing antibiotic regimens presents a powerful multi-pronged approach to combating bacterial infections. This combined use of mAbs with antibiotic therapy builds evolutionary barriers against bacteria, reducing the likelihood of treatment failure due to the development of drug-resistant strains (Zurawski and McLendon, 2020b; Zurawski and McLendon, 2020a). The synergistic effect of this approach offers several benefits, including reduced antibiotic usage, enhanced bacterial clearance, and immunomodulation. As research in this field progresses, these advanced mAb strategies hold the promise of ushering in a new era of targeted, efficient, and resistance-proof therapies for bacterial infections, potentially revolutionizing our approach to combating the global challenge of antimicrobial resistance.

V. NOVEL MONOCLONAL ANTIBODY FORMATS IN COMBATING BACTERIAL INFECTION




Several novel mAb formats have gained significant attention in recent years, including antibody-drug conjugates, bispecific mAbs, IgY, nanobodies, and single-chain variable fragments (scFv) (Table 2).

- **Antibody-Drug Conjugates:** These involve drugs or toxins covalently attached to immunoglobulins, allowing for targeted delivery to specific sites. This technique shows great promise for killing cancer cells or microbes (Tvilum et al., 2023).
- **Bispecific mAbs:** These combine two distinct mAbs to simultaneously target two different proteins, enabling multiple physiological or anti-tumor responses by engaging two antigens or epitopes at once (DiGiandomenico et al., 2014b).
- **IgY:** This is an immunoglobulin found in birds and reptiles, showing potential applications in treating *P. aeruginosa* and *S. aureus* infections (Amro et al., 2018) (Zhen et al., 2008);



- **Thomsen et al., 2016a):** These are single-domain antigen-binding fragments derived from camelid heavy-chain antibodies, offering advantages such as small size, high stability, and ease of production (Salvador et al., 2019).
- **Single-Chain Variable Fragments (scFv):** These are fusion proteins of the variable regions of the heavy and light chains of immunoglobulins, while single-domain antibodies (sdAb) consist of either a light chain or heavy chain variable region (Satheeshkumar, 2020). scFv molecules have shown promise in treating neovascular age-related macular degeneration (Tadayoni et al., 2021).

Each of these novel mAb types possesses unique characteristics and advantages. Antibody-drug conjugates are particularly effective in targeting and delivering cytotoxic agents to cancer cells or pathogens. Bispecific mAbs can elicit multiple immune responses by targeting two different antigens simultaneously. IgY antibodies hold potential for specific bacterial infections. Nanobodies, due to their small size and high stability (enhancements like PEGylation or fusion with albumin-binding domains can extend its circulation time), are advantageous for various applications. scFv molecules are being explored for their efficacy in treating complex conditions like neovascular age-related macular degeneration.

Table 2: The Novel Types of mAbs

Novel mAbs Types		Characteristics	Example	Advantages	Disadvantages	Ref.
Antibody-Drug conjugation		Delivering drugs directly to specific antigens.	DSTA4637A / MRSA / Human IgG1-dmDNA31	<ol style="list-style-type: none"> 1. Potentially minimizes the side effects associated with antibiotics. 2. Remains stable in circulation. 3. Revives antibiotics that exhibit poor pharmacokinetic properties or cause undesired host toxicity. 	<ol style="list-style-type: none"> 1. The effectiveness is limited by the abundance of antigens on bacterial cell surfaces. 2. Comprises various components with distinct chemical characteristics. 3. Presents challenges in manufacturing. 	(Mariathas and Tan, 2017) (Cavaco, et al., 2022)
Bispecific mAbs		Simultaneously binds to two different epitopes using a mAb.	MEDI3902 / <i>P. aeruginosa</i> PcrV & Psl	<ol style="list-style-type: none"> 1. Alternative therapeutic approach, substituting combination therapy with two monospecific drugs. 2. Sensitive immunoassays enable swift and straightforward detection of infectious diseases. 	<ol style="list-style-type: none"> 1. Production by two separate cell lines makes it costly and challenging to harvest. 2. Potential for decreased stability or susceptibility to aggregation. 	(DiGiandomenico et al., 2014a) (Nyakatura et al., 2017) (Sedykh et al., 2018)
IgY		Highly conserved to human IgG.	PsAer-IgY / <i>P. aeruginosa</i> surface protein (Flagellin)	<ol style="list-style-type: none"> 1. Low-cost and minimal production effort. 2. Rapid production is feasible for acute illnesses. 3. Lower background of cross-reactivity. 	<ol style="list-style-type: none"> 1. Possibility of host-produced anti-IgY antibodies.. 2. Unable to activate human Fc receptors and the complement system. 	(Thomsen et al., 2016b) (Lee et al., 2021)

MONOCLONAL ANTIBODIES: A PROMISING WEAPON AGAINST
THE SILENT PAN-DEMIC OF MULTIDRUG-RESISTANT BACTERIA

<p>Nanobody</p>		<p>Antibody lack of light chain and constant domain.</p>	<p>NbD7 / <i>Ehrlichia chaffeensis</i> translocated factor-1</p>	<ol style="list-style-type: none"> 1. Reaches or concealed epitopes inaccessible to traditional mAbs. 2. Exhibits remarkable stability, hydrophilicity, and solubility, contributing to sustained binding capacity. 3. Diverse expression systems. 	<ul style="list-style-type: none"> . High uptake in kidney. . Risk of immunogenicity. 	<p>(Salvador, et al., 2019) (Mei et al., 2022)</p>
<p>scFv</p>		<p>An antibody comprises only the variable regions of the heavy and light chains.</p>	<p>Brolucizumab / Neovascular Age-related Macular Degeneration VEGF- A</p>	<ol style="list-style-type: none"> 1. Preserves the original antibody's binding affinity and specificity. 2. Easily constructed, expressed, and manufactured in large quantities. 	<ol style="list-style-type: none"> 1. Limited half-life and low stability in circulation. 2. Requires high doses and continuous administration. 	<p>(Ahmad et al., 2012) (Tadayoni, et al., 2021) (Muñoz-López et al., 2022)</p>

While novel mAb types offer promising avenues for combating MDR bacteria, each variant comes with its own set of challenges that researchers must address. ADCs, despite their potential for targeted drug delivery, face hurdles in maintaining drug stability and minimizing off-target effects, which can lead to unintended toxicity in healthy tissues (Kim and Kim, 2015). The complex architecture of bispecific mAbs, while allowing for dual-targeting capabilities, presents significant manufacturing difficulties, often resulting in low yields and high production costs (DiGiandomenico, et al., 2014b). IgY antibodies, derived from avian sources, show promise in their broad-spectrum activity, but concerns persist regarding their potential immunogenicity in humans and the complexity of their purification process (Amro, et al., 2018). Nanobodies, despite their small size and stability, may struggle with limited tissue penetration, potentially reducing their efficacy against deep-seated infections. Additionally, their non-human origin could trigger immune responses in patients, necessitating careful humanization strategies (Salvador, et al., 2019). Single-chain variable fragments (scFv), while offering enhanced tissue penetration due to their small size, are prone to aggregation and exhibit significantly shorter half-lives compared to full-length antibodies, potentially requiring more frequent dosing to maintain therapeutic levels (Satheeshkumar, 2020). Despite these challenges, the unique properties of these novel mAb types present distinct opportunities for therapeutic interventions against MDR bacteria. ADCs, for instance, could revolutionize the delivery of antimicrobial agents directly to pathogens, potentially reducing systemic toxicity. Bispecific mAbs offer the possibility of simultaneously targeting multiple bacterial epitopes or engaging both the pathogen and the host immune system, potentially enhancing clearance of resistant strains. IgY antibodies, with their evolutionary distance from mammalian antibodies, might provide novel binding sites for conserved bacterial targets that have evaded traditional mAb approaches. Nanobodies, with their exceptional stability and ability to recognize unique epitopes, could prove valuable in developing new diagnostic tools or as building blocks for more complex antibody constructs. scFv molecules, despite their limitations, offer potential in phage display technologies for rapid selection of high-affinity binders against emerging pathogens. As we navigate the post-COVID era, where the threat of MDR bacteria looms larger than ever, continued research and development efforts are crucial to fully harness the potential of these novel mAb types. By addressing their respective drawbacks and leveraging their unique

advantages, we may uncover innovative solutions to combat antibiotic resistance and develop more effective therapies against bacterial infections.

VI. SYNERGIZING ANTIBACTERIAL MABS WITH EMERGING TECHNOLOGIES

Recent advancements in cutting-edge technologies have significantly impacted the field of antibacterial mAbs, offering novel approaches to enhance their efficacy in combating bacterial infections. The integration of nanotechnology, artificial intelligence (AI), and CRISPR-Cas gene-editing systems with mAb development and application has opened up promising avenues for addressing the challenges posed by MDR bacterial pathogens. Nanotechnology has emerged as a powerful tool for augmenting the therapeutic potential of antibacterial mAbs. Engineered nanoparticles serve as effective carriers, facilitating targeted delivery of mAbs to infection sites and potentially improving their therapeutic index [76]. Furthermore, nanoparticles functionalized with mAbs can act as 'molecular traps' for bacterial toxins or whole bacteria, offering a novel approach to pathogen clearance [77]. The concept of theranostics, combining diagnostic and therapeutic capabilities, has been realized through the integration of mAbs with nanoparticles, enabling simultaneous detection and treatment of bacterial infections [78].

The development of antibacterial mAbs is being revolutionized by AI and machine learning (ML). AI has significantly impacted antibody design through various approaches, with ML models now being used to optimize critical antibody properties such as affinity, specificity, and developability (Makowski et al., 2022). These models can predict antibody characteristics using sequences or structures, allowing for the early identification of promising candidates (Kim et al., 2023b). Advanced AI-driven platforms have been developed to jointly generate antibody sequences and structures while considering the target epitope, enabling more efficient and targeted antibody design (Akbar et al., 2022). AI has also revolutionized the antibody discovery process by enabling the rapid production of antibodies through deep generative models, generating large volumes of antigen-specific data efficiently and reducing reliance on traditional experimental methods (Li et al., 2023). Moreover, AI has been instrumental in predicting immunogenicity, a crucial aspect in evaluating the safety and efficacy of antibody therapeutics, by recognizing B and T cell epitopes that may trigger an immunogenic response (Kim, et al., 2023b). The synergy between AI and other emerging technologies is further amplifying the potential of antibacterial mAbs. The combination of AI with high-throughput screening technologies and advanced structural biology techniques is enabling more rapid and accurate characterization of antibody-antigen interactions (Bennett et al., 2024). Additionally, the integration of AI with nanotechnology is opening new avenues for targeted delivery of antibacterial mAbs, potentially improving their efficacy against intracellular pathogens or biofilm-associated bacteria. As AI and ML technologies continue to evolve, we can anticipate even more sophisticated applications in antibacterial mAb development. Future directions may include AI-driven personalized antibody therapies tailored to individual patient microbiomes and immune profiles, real-time adaptation of antibody designs in response to emerging bacterial resistance patterns, and integration of AI with synthetic biology techniques for on-demand production of antibacterial mAbs. By enabling more efficient and targeted antibody development, optimizing key properties, predicting immunogenicity, and streamlining the discovery process, these technologies are accelerating our ability to combat multidrug-

resistant bacterial infections (Makowski, et al., 2022). As these fields continue to advance, we can expect increasingly sophisticated and effective antibacterial mAb therapies to emerge, offering new hope in the fight against antibiotic-resistant pathogens. In the clinical domain, AI facilitates patient stratification and outcome prediction in trials of antibacterial mAbs, potentially expediting the drug development process [80].

The convergence of mAb technology with CRISPR-Cas gene-editing systems presents intriguing possibilities for targeted bacterial therapeutics. mAbs could potentially serve as delivery vehicles for CRISPR-Cas systems, enabling precise targeting of pathogenic bacteria. Furthermore, this combination might offer a means to reverse antibiotic resistance genes in bacteria, addressing one of the most pressing challenges in infectious disease management [81].

These technological integrations collectively represent a paradigm shift in the approach to antibacterial mAb development and application. By leveraging nanotechnology, AI, and gene-editing technologies, researchers and clinicians are poised to enhance the discovery, development, and therapeutic efficacy of mAbs in combating MDR bacterial infections. This synergistic approach holds promise for overcoming current limitations and ushering in a new era of targeted, effective antibacterial therapies.

VII. SHORTCOMINGS AND FUTURE PROSPECTS OF ANTIBACTERIAL MONOCLONAL ANTIBODIES

The emergence of mAb-based immunotherapy as a potential solution to combat MDR bacterial infections has sparked considerable interest in the medical community. However, this promising field faces several significant hurdles that researchers must overcome to fully realize its therapeutic potential. One primary concern is the persistent risk of HACA responses, even with the use of humanized mAbs. These responses can potentially compromise treatment efficacy and pose safety risks to patients (Mahdizade Ari et al., 2024). Another critical challenge lies in the highly specific nature of mAb targets, which often correspond to antigens unique to particular bacterial species or strains. This specificity necessitates rapid and precise pathogen identification to ensure appropriate mAb selection. Furthermore, the expression of target antigens may be limited to specific bacterial strains, infection sites, or stages of disease progression, potentially restricting the efficacy of mAb therapies. A case in point is KB001-A, an antibody targeting the type 3 secretion system protein PcrV of *Pseudomonas aeruginosa*. While this mAb showed promise in reducing ventilator-associated *P. aeruginosa* pneumonia, its efficacy was notably diminished in cystic fibrosis patients, highlighting the complexity of translating laboratory success to diverse clinical scenarios (Cao et al., 2017).

The structural intricacies of bacterial cell surfaces present additional obstacles in mAb development. Many promising targets, such as highly conserved outer membrane proteins, are often shielded by complex carbohydrate structures, limiting antibody accessibility. This challenge is further compounded by the remarkable diversity of exopolysaccharide structures among different bacterial serotypes. For instance, *S. pneumoniae*, a leading cause of pneumonia and meningitis, produces a protective capsule composed of variable exopolysaccharides crucial for its virulence and immune evasion strategies. The heterogeneity of these capsular structures across *S. pneumoniae* serotypes suggests that

developing a single mAb capable of broad-spectrum protection against this pathogen may be exceedingly difficult. However, some researchers have focused on targeting more conserved bacterial structures. One such target is PNAG, an exopolysaccharide found in numerous pathogens and linked to their survival, toxicity, and biofilm formation capabilities. The development of IgG1 mAb F598, which targets deacetylated synthetic PNAG, demonstrated promising results across various microbial challenge models. Despite its potential, F598 did not progress beyond Phase 2 clinical trials, under scoring the complex journey from preclinical promise to clinical success. Nevertheless, the insights gained from such studies continue to inform future mAb development strategies. As the field advances, researchers are exploring innovative approaches to address these challenges, including the development of mAb cocktails targeting multiple epitopes, the use of artificial intelligence in antibody design, and the integration of mAb therapies with traditional antibiotics to enhance overall efficacy against MDR pathogens (Singh et al., 2018).

VIII. GLOBAL HEALTH IMPACT: ANTIBACTERIAL MABS IN DIVERSE HEALTHCARE SETTINGS

Antibacterial mAbs have the potential to significantly impact healthcare in low- and middle-income countries by providing targeted treatment options for bacterial infections, which are often prevalent in these regions (Wang-Lin and Balthasar, 2018). The use of monoclonal antibodies as an antibacterial approach holds promise in addressing region-specific bacterial threats, offering a targeted and effective means to combat various pathogens (Zurawski and policies of government regulators to reduce commercial McLendon, 2020b). One of the key challenges in the global distribution and access to antibacterial mAbs lies in ensuring equitable availability and affordability, especially in resource-limited settings. Overcoming logistical and financial barriers is crucial to ensure widespread access to these life-saving treatments (Johnson et al., 2023). Future directions in the field of antibacterial mAbs may involve further research into novel antibody-peptide combinations for targeting specific bacterial strains, as well as exploring innovative strategies to enhance the efficacy and accessibility of these treatments globally. Breakthroughs in antibody development and antimicrobial peptide fusion could pave the way for more effective and accessible antibacterial therapies in diverse healthcare settings (Johnson, et al., 2023). Similar to the problems observed for vaccines and antibiotics, commercial investment tends to be influenced by market size of the disease. Therefore, the development of broad-spectrum mAbs needs to be guided by the barriers and enable related fields to blossom. This remains an open question that requires addressing in the foreseeable future.

IX. CONCLUSION

The journey of mAbs in combating MDR bacterial infections stands at a critical juncture. As we've explored throughout this review, the potential of mAbs to revolutionize our approach to treating resistant infections is substantial, yet not without challenges. The landscape of antibacterial mAbs is rapidly evolving. From the early days of mouse-derived antibodies to the current era of fully human and engineered antibodies, we've witnessed remarkable progress. The success stories, such as bezlotoxumab for *C. difficile* infections, provide a glimpse of what's possible. However, the road ahead demands innovation, persistence, and a willingness to challenge conventional therapeutic paradigms. One intriguing avenue for future research lies in the development of 'smart' mAbs capable of distinguishing between

commensal and pathogenic bacteria. Such precision could revolutionize treatment, minimizing disruption to the beneficial microbiome while effectively targeting harmful pathogens. Imagine antibodies that not only neutralize bacteria but also modulate the host immune response, enhancing natural defenses against infection. The potential synergy between mAbs and other emerging technologies is another frontier ripe for exploration. Could we see nanoparticle mAb conjugates that more effectively penetrate biofilms? Or mAbs engineered to carry CRISPR-Cas payloads, capable of editing bacterial genomes to reverse antibiotic resistance? These may seem like science fiction today, but so did many of our current medical marvels just a few decades ago. As we look to the future, the global health implications of mAb therapies cannot be overstated. Their potential to address region-specific bacterial threats could transform healthcare in resource-limited settings. However, realizing this potential will require overcoming significant hurdles in production, distribution, and affordability. Innovative approaches, such as plant-based antibody production or the development of thermostable formulations, could be game-changers in expanding access. The road ahead for antibacterial mAbs is not without obstacles. Regulatory frameworks must evolve to keep pace with technological advancements. The economic realities of drug development continue to pose challenges, particularly for therapies targeting fewer common pathogens. Collaboration between academia, industry, and government agencies will be crucial in overcoming these hurdles. Moreover, as we delve deeper into the complexities of host-pathogen interactions, our understanding of how to best deploy mAb therapies will undoubtedly evolve. Could personalized approaches, tailored to an individual's microbiome or immune profile, become the norm? Might we see combination therapies that pair mAbs with traditional antibiotics or other novel antimicrobials, creating synergistic effects that overcome resistance mechanisms?

In conclusion, while the challenges are significant, the potential rewards of advancing mAb therapies for MDR bacterial infections are immense. As researchers, clinicians, and policymakers, we stand at the threshold of a new era in infectious disease treatment. By embracing innovation, fostering collaboration, and maintaining a patient-centered focus, we can work towards a future where MDR infections no longer pose the existential threat they do today.

The journey of antibacterial mAbs is far from over; in many ways, it's just beginning. As we move forward, let us approach this challenge with the urgency it demands, the creativity it requires, and the hope it inspires. The next chapter in the story of antibacterial mAbs is ours to write, and its impact could reshape the landscape of global health for generations to come.

MONOCLONAL ANTIBODIES: A PROMISING WEAPON AGAINST
THE SILENT PAN-DEMIC OF MULTIDRUG-RESISTANT BACTERIA



REFERENCES

- [1] Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. 2012. scFv antibody: principles and clinical application. *Clin Dev Immunol* 2012:980250.
- [2] Akbar R, Robert PA, Weber CR, Widrich M, Frank R, Pavlovic M, Scheffer L, Chernigovskaya M, Snapkov I, Slabodkin A, Mehta BB, Miho E, Lund-Johansen F, Andersen JT, Hochreiter S, Hobaek Haff I, Klambauer G, Sandve GK, Greiff V. 2022. In silico proof of principle of machine learning-based antibody design at unconstrained scale. *MABs* 14:2031482.
- [4] Amro WA, Al-Qaisi W, Al-Razem F. 2018. Production and purification of IgY antibodies from chicken egg yolk. *J Genet Eng Biotechnol* 16:99-103.
- [5] Anderson JDIV, Bagamian KH, Pecenka CJ, Muhib F, Puett CA, Hausdorff WP, Scheele S. 2023. Potential impact and cost-effectiveness of *Shigella* vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: a modelling study. *The Lancet Global Health* 11:e880-e891.
- [6] Antimicrobial Resistance C. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*
- [7] Antinori A, Bausch-Jurken M. 2023. The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future. *J Infect Dis* 228:S4-S12.
- [8] Bajema KL, Gierke R, Farley MM, Schaffner W, Thomas A, Reingold AL, Harrison LH, Lynfield R, Burzlaff KE, Petit S, Barnes M,
- [9] Torres S, Vagnone PMS, Beall B, Pilishvili T. 2022. Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible
- [10] Invasive Pneumococcal Disease in the United States. *J Infect Dis* 226:342-351.
- [11] Batchelder JI, Hare PJ, Mok WWK. 2023. Resistance-resistant antibacterial treatment strategies. *Front Antibiot* 2
- [12] Bennett NR, Watson JL, Ragotte RJ, Borst AJ, See DL, Weidle C, Biswas R, Shrock EL, Leung PJY, Huang B, Goreshnik I, Ault R,
- [13] Carr KD, Singer B, Criswell C, Vafeados D, Sanchez MG, Kim HM, Torres SV, Chan S, Baker D. 2024. Atomically accurate de novo design of single-domain antibodies. *bioRxiv*
- [14] Buchy P, Ascioğlu S, Buisson Y, Datta S, Nissen M, Tambyah PA, Vong S. 2020. Impact of vaccines on antimicrobial resistance. *Int J Infect Dis* 90:188-196.
- [15] Buckley PT, Chan R, Fernandez J, Luo J, Lacey KA, DuMont AL, O'Malley A, Brezski RJ, Zheng S, Malia T, Whitaker B, Zwolak A,
- [17] Payne A, Clark D, Sigg M, Lacy ER, Kornilova A, Kwok D, McCarthy S, Wu B, Morrow B, Nemeth-Seay J, Petley T, Wu S, Strohl
- [18] WR, Lynch AS, Torres VJ. 2023. Multivalent human antibody-centyrin fusion protein to prevent and treat *Staphylococcus aureus* infections. *Cell Host Microbe* 31:751-765 e711.

- [19] Butler MS, Henderson IR, Capon RJ, Blaskovich MAT. 2023. Antibiotics in the clinical pipeline as of December 2022. *J Antibiot (Tokyo)* 76:431-473.
- [20] Cao J, Yi F, Tian Q, Dang G, Si W, Liu S, Yu S. 2017. Targeting the gram-negative bacteria peptidoglycan synthase MraY as a new approach for monoclonal antibody anti-bacterial activity. *Hum Vaccin Immunother* 13:2086-2091.
- [21] Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME,
- [22] Devleeschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL, Burden of AMRCG. 2019.
- [23] Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the
- [24] European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect Dis* 19:56-66.
- [25] Cavaco M, Castanho M, Neves V. 2022. The Use of Antibody-Antibiotic Conjugates to Fight Bacterial Infections. *Front Microbiol* 13:835677.
- [26] CDC. 2019. Antibiotic resistance threats in the United States 2019. US Centers for Disease Control and Prevention (CDC), Atlanta.
- [27] URL: <http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf> [accessed 20 February 2019].
- [28] CDC. 2022. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Atlanta, GA.
- [29] Chiang MH, Sung WC, Lien SP, Chen YZ, Lo AF, Huang JH, Kuo SC, Chong P. 2015. Identification of novel vaccine candidates against *Acinetobacter baumannii* using reverse vaccinology. *Hum Vaccin Immunother* 11:1065-1073.
- [30] Chungyoun M, Gray JJ. 2023. AI Models for Protein Design are Driving Antibody Engineering. *Curr Opin Biomed Eng* 28
- [31] Davies NG, Flasche S, Jit M, Atkins KE. 2021. Modeling the effect of vaccination on selection for antibiotic resistance in *Streptococcus pneumoniae*. *Sci Transl Med* 13
- [32] DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrenner P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman
- [33] BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu X-Q, Suzich JA, Stover CK. 2014a. A multifunctional bispecific antibody protects against *Pseudomonas aeruginosa*. *Science Translational Medicine* 6:262ra155-262ra155.
- [34] DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrenner P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman
- [35] BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK. 2014b. A multifunctional bispecific antibody protects against *Pseudomonas aeruginosa*. *Sci Transl Med* 6:262ra155.
- [36] Elemam NM, Ramakrishnan RK, Hundt JE, Halwani R, Maghazachi AA, Hamid Q. 2021. Innate Lymphoid Cells and Natural Killer
- [37] Cells in Bacterial Infections: Function, Dysregulation, and Therapeutic Targets. *Front Cell Infect Microbiol* 11:733564.
- [38] Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T. 2002.
- [39] Generation and characterization of a protective monoclonal antibody to *Pseudomonas aeruginosa* PcrV. *J Infect Dis* 186:64-73.
- [40] Frost I, Sati H, Garcia-Vello P, Hasso-Agopsowicz M, Lienhardt C, Gigante V, Beyer P. 2023. The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline. *Lancet Microbe* 4:e113-e125.
- [41] Ghoneim HE, Thomas PG, McCullers JA. 2013. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. *J Immunol* 191:1250-1259.
- [42] Gilchuk P, Murin CD, Milligan JC, Cross RW, Mire CE, Ilinykh PA, Huang K, Kuzmina N, Altman PX, Hui S, Gunn BM, Bryan AL,
- [43] Davidson E, Doranz BJ, Turner HL, Alkutkar T, Flinko R, Orlandi C, Carnahan R, Nargi R, Bombardi RG, Vodzak ME, Li S, Okoli
- [44] A, Ibeawuchi M, Ohiaeri B, Lewis GK, Alter G, Bukreyev A, Sapphire EO, Geisbert TW, Ward AB, Crowe JE, Jr. 2020. Analysis of a
- [45] Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. *Immunity* 52:388-403 e312.

- [46] Harding FA, Stickler MM, Razo J, DuBridge RB. 2010. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. *MAbs* 2:256-265.
- [47] Huang W, Zhang Q, Li W, Chen Y, Shu C, Li Q, Zhou J, Ye C, Bai H, Sun W, Yang X, Ma Y. 2019. Anti-outer Membrane Vesicle
- [48] Antibodies Increase Antibiotic Sensitivity of Pan-Drug-Resistant *Acinetobacter baumannii*. *Front Microbiol* 10:1379.
- [49] Hwang WY, Foote J. 2005. Immunogenicity of engineered antibodies. *Methods* 36:3-10.
- [50] Jansen KU, Knirsch C, Anderson AS. 2018. The role of vaccines in preventing bacterial antimicrobial resistance. *Nat Med* 24:10-19.
- [51] Johnson K, Delaney JC, Guillard T, Reffuveille F, Varin-Simon J, Li K, Wollacott A, Frapy E, Mong S, Tissire H, Viswanathan K,
- [52] Touti F, Babcock GJ, Shriver Z, Pentelute BL, Plante O, Skurnik D. 2023. Development of an antibody fused with an antimicrobial peptide targeting *Pseudomonas aeruginosa*: A new approach to prevent and treat bacterial infections. *PLoS Pathog* 19:e1011612.
- [53] Kang TH, Seong BL. 2020. Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms. *Front Microbiol* 11:1927.
- [54] Kennedy DA, Read AF. 2017. Why does drug resistance readily evolve but vaccine resistance does not? *Proc Biol Sci* 284
- [55] Kim C, Holm M, Frost I, Hasso-Agopsowicz M, Abbas K. 2023a. Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study. *BMJ Glob Health* 8
- [56] Kim EG, Kim KM. 2015. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. *Biomol Ther (Seoul)* 23:493-509.
- [57] Kim J, McFee M, Fang Q, Abdin O, Kim PM. 2023b. Computational and artificial intelligence-based methods for antibody development. *Trends Pharmacol Sci* 44:175-189.
- [58] Klemm J, Pekar L, Krah S, Zielonka S. 2021. Antibody Display Systems. In: Rüker F, Wozniak-Knopp G (Editors). *Introduction to Antibody Engineering*. Cham: Springer International Publishing, p 65-96.
- [59] Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, Daneman N, MacFadden DR. 2021. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. *Clin Microbiol Infect* 27:520-531.
- [60] Lee J-S, Mogasale V, Kim S, Cannon J, Giannini F, Abbas K, Excler J-L, Kim JH. 2023. The potential global cost-effectiveness of prospective Strep A vaccines and associated implementation efforts. *npj Vaccines* 8:128.
- [61] Lee L, Samardzic K, Wallach M, Frumkin LR, Mochly-Rosen D. 2021. Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases. *Front Immunol* 12
- [62] Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Hiroshi Morisaki J, Kim J, Park
- [63] S, Darwish M, Lee B-C, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J,
- [64] Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S. 2015. Novel antibody-antibiotic conjugate eliminates intracellular *S. aureus*. *Nature* 527:323-328.
- [65] Li L, Gupta E, Spaeth J, Shing L, Jaimes R, Engelhart E, Lopez R, Caceres RS, Bepler T, Walsh ME. 2023. Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries. *Nat Commun* 14:3454.
- [66] Little SF, Webster WM, Fisher DE. 2011. Monoclonal antibodies directed against protective antigen of *Bacillus anthracis* enhance lethal toxin activity in vivo. *FEMS Immunol Med Microbiol* 62:11-22.
- [67] López-Siles M, Corral-Lugo A, McConnell MJ. 2020. Vaccines for multidrug resistant Gram negative bacteria: lessons from the past for guiding future success. *FEMS Microbiol Rev* 45:fuaa054.
- [68] Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. 2020. Development of therapeutic antibodies for the treatment of diseases. *J Biomed Sci* 27:1.
- [69] Mahdizade Ari M, Amini ME, Sholeh M, Zahedi Bialvaei A. 2024. The effect of polyclonal and monoclonal based antibodies as promising potential therapy for treatment of sepsis: A systematic review. *New Microbes New Infect* 60-61:101435.
- [70] Mak IW, Evaniew N, Ghert M. 2014. Lost in translation: animal models and clinical trials in cancer treatment. *Am J Transl Res* 6:114-118.
- [71] Makowski EK, Kinnunen PC, Huang J, Wu L, Smith MD, Wang T, Desai AA, Streu CN, Zhang Y, Zupancic JM, Schardt JS,

- [72] Linderman JJ, Tessier PM. 2022. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. *Nat Commun* 13:3788.
- [73] Mariathasan S, Tan MW. 2017. Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections. *Trends Mol Med* 23:135-149.
- [74] Maynard AWNaJA. 2021. Protein Engineering: Tools and Applications. WILEY-VCH GmbH. 317-351 p.
- [75] McConnell MJ. 2019. Where are we with monoclonal antibodies for multidrug-resistant infections? *Drug Discov Today* 24:1132-1138.
- [76] McCulloch TR, Wells TJ, Souza-Fonseca-Guimaraes F. 2022. Towards efficient immunotherapy for bacterial infection. *Trends Microbiol* 30:158-169.
- [77] Medicine UNLo. 2023. ClinicalTrials.gov. URL: <https://clinicaltrials.gov> [accessed August 7 2023].
- [78] Mei Y, Chen Y, Sivaccumar JP, An Z, Xia N, Luo W. 2022. Research progress and applications of nanobody in human infectious diseases. *Front Pharmacol* 13:963978.
- [79] Michalik M, Djahanshiri B, Leo JC, Linke D. 2016. Reverse Vaccinology: The Pathway from Genomes and Epitope Predictions to Tailored Recombinant Vaccines. *Methods Mol Biol* 1403:87-106.
- [80] Monserrat-Martinez A, Gambin Y, Siernecki E. 2019. Thinking Outside the Bug: Molecular Targets and Strategies to Overcome
- [81] Antibiotic Resistance. *Int J Mol Sci* 20
- [82] Motley MP, Banerjee K, Fries BC. 2019. Monoclonal antibody-based therapies for bacterial infections. *Curr Opin Infect Dis* 32:210- 216.
- [83] Muñoz-López P, Ribas-Aparicio RM, Becerra-Báez EI, Fraga-Pérez K, Flores-Martínez LF, Mateos-Chávez AA, Luria-Pérez R. 2022.
- [84] Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy. *Cancers (Basel)* 14
- [85] Nyakatura EK, Soare AY, Lai JR. 2017. Bispecific antibodies for viral immunotherapy. *Hum Vaccin Immunother* 13:836-842.
- [86] O'Neill J. 2014. Review on Antimicrobial Resistance Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. London.
- [87] Orth P, Xiao L, Hernandez LD, Reichert P, Sheth PR, Beaumont M, Yang X, Murgolo N, Ermakov G, DiNunzio E, Racine F,
- [88] Karczewski J, Secore S, Ingram RN, Mayhood T, Strickland C, Therien AG. 2014. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. *J Biol Chem* 289:18008-18021.
- [89] Pasero D, Cossu AP, Terragni P. 2021. Multi-Drug Resistance Bacterial Infections in Critically Ill Patients Admitted with COVID-19.
- [90] Microorganisms 9
- [91] Pietrzykowski M, Flanagan W, Pizzi V, Brown A, Sinclair A, Monge M. 2013. An environmental life cycle assessment comparison of single-use and conventional process technology for the production of monoclonal antibodies. *Journal of Cleaner Production* 41:150-162.
- [92] Raafat D, Otto M, Reppschlager K, Iqbal J, Holtfreter S. 2019. Fighting Staphylococcus aureus Biofilms with Monoclonal Antibodies. *Trends Microbiol* 27:303-322.
- [93] Ryser S, Tenorio E, Estelles A, Kauvar LM. 2019. Human antibody repertoire frequently includes antibodies to a bacterial biofilm associated protein. *PLoS One* 14:e0219256.
- [94] Saha SK, Tabassum N, Saha S. 2021. Typhoid Conjugate Vaccine: An Urgent Tool to Combat Typhoid and Tackle Antimicrobial
- [95] Resistance. *The Journal of Infectious Diseases* 224:S788-S791.
- [96] Salvador JP, Vilaplana L, Marco MP. 2019. Nanobody: outstanding features for diagnostic and therapeutic applications. *Anal Bioanal Chem* 411:1703-1713.
- [97] Satheeshkumar PK. 2020. Expression of Single Chain Variable Fragment (scFv) Molecules in Plants: A Comprehensive Update. *Mol Biotechnol* 62:151-167.
- [98] Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. 2018. Bispecific antibodies: design, therapy, perspectives. *Drug Design, Development and Therapy* 12:195-208.
- [99] Seixas AMM, Sousa SA, Leitao JH. 2022. Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections. *Vaccines (Basel)* 10
- [100] Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK. 2018. Monoclonal Antibodies: A Review. *Curr Clin Pharmacol* 13:85-99.
- [101] Soliman C, Pier GB, Ramsland PA. 2020. Antibody recognition of bacterial surfaces and extracellular polysaccharides. *Curr Opin*
- [102] *Struct Biol* 62:48-55.

- [103] Stokes JM, Lopatkin AJ, Lobritz MA, Collins JJ. 2019. Bacterial Metabolism and Antibiotic Efficacy. *Cell Metab* 30:251-259.
- [104] Szióártó V, Nagy E, Nagy G. 2018. Directly Bactericidal Anti-*Escherichia coli* Antibody. *Trends in Microbiology* 26:642-644.
- [105] Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. 2021. Brolicizumab: A Newly Developed Anti-VEGF
- [106] Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. *Ophthalmologica* 244:93-101.
- [107] Thomsen K, Christophersen L, Bjarnsholt T, Jensen PO, Moser C, Hoiby N. 2016a. Anti-*Pseudomonas aeruginosa* IgY antibodies augment bacterial clearance in a murine pneumonia model. *J Cyst Fibros* 15:171-178.
- [108] Thomsen K, Christophersen L, Bjarnsholt T, Jensen PØ, Moser C, Høiby N. 2016b. Anti-*Pseudomonas aeruginosa* IgY antibodies augment bacterial clearance in a murine pneumonia model. *Journal of Cystic Fibrosis* 15:171-178.
- [109] Tvilum A, Johansen MI, Glud LN, Ivarsen DM, Khamas AB, Carmali S, Mhatre SS, Sogaard AB, Faddy E, de Vor L, Rooijackers
- [110] SHM, Ostergaard L, Jorgensen NP, Meyer RL, Zelikin AN. 2023. Antibody-Drug Conjugates to Treat Bacterial Biofilms via
- [111] Targeting and Extracellular Drug Release. *Adv Sci (Weinh)* 10:e2301340.
- [112] Vacca F, Sala C, Rappuoli R. 2022. Monoclonal Antibodies for Bacterial Pathogens: Mechanisms of Action and Engineering
- [113] Approaches for Enhanced Effector Functions. *Biomedicines* 10
- [114] Wang-Lin SX, Balthasar JP. 2018. Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections. *Antibodies (Basel)* 7
- [115] Wang H, Chen D, Lu H. 2022. Anti-bacterial monoclonal antibodies: next generation therapy against superbugs. *Applied Microbiology and Biotechnology* 106:3957-3972.
- [116] Warrener P, Varkey R, Bonnell JC, DiGiandomenico A, Camara M, Cook K, Peng L, Zha J, Chowdury P, Sellman B, Stover CK.
- [117] 2014. A novel anti-PcrV antibody providing enhanced protection against *Pseudomonas aeruginosa* in multiple animal infection models. *Antimicrob Agents Chemother* 58:4384-4391.
- [118] Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim
- [119] YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB, Modify I, Investigators MI. 2017.
- [120] Bezlotoxumab for Prevention of Recurrent *Clostridium difficile* Infection. *N Engl J Med* 376:305-317.
- [121] Yadav PD, Mendiratta SK, Mohandas S, Singh AK, Abraham P, Shete A, Bandyopadhyay S, Kumar S, Parikh A, Kalita P, Sharma
- [122] V, Pandya H, Patel CG, Patel M, Soni S, Giri S, Jain M. 2021. ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in
- [123] Syrian Hamsters against SARS-CoV-2 Infection. *Viruses* 13
- [124] Yang Y, Qian M, Yi S, Liu S, Li B, Yu R, Guo Q, Zhang X, Yu C, Li J, Xu J, Chen W. 2016. Monoclonal Antibody Targeting
- [125] *Staphylococcus aureus* Surface Protein A (SasA) Protect Against *Staphylococcus aureus* Sepsis and Peritonitis in Mice. *PLoS One* 11:e0149460.
- [126] Zhen YH, Jin LJ, Guo J, Li XY, Li Z, Fang R, Xu YP. 2008. Characterization of specific egg yolk immunoglobulin (IgY) against mastitis-causing *Staphylococcus aureus*. *J Appl Microbiol* 105:1529-1535.
- [127] Zhou C, Lehar S, Gutierrez J, Rosenberger CM, Ljumanovic N, Dinoso J, Koppada N, Hong K, Baruch A, Carrasco-Triguero M,
- [128] Saad O, Mariathasan S, Kamath AV. 2016. Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against *Staphylococcus aureus* in mice. *MAbs* 8:1612-1619.
- [129] Zurawski DV, McLendon MK. 2020a. Monoclonal antibodies as an antibacterial approach against bacterial pathogens. *Antibiotics* 9:155.
- [130] Zurawski DV, McLendon MK. 2020b. Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens. *Antibiotics (Basel)* 9